Article
Best Peptides for Longevity Research
Important regulatory notice. No peptide is currently licensed by the MHRA as a longevity or anti-ageing medicine in the United Kingdom. This page is a literature-context overview of compound families…
This is the text in its original language.
Important regulatory notice. No peptide is currently licensed by the MHRA as a longevity or anti-ageing medicine in the United Kingdom. This page is a literature-context overview of compound families discussed in published longevity research. It is not personal-use guidance, and no human or veterinary use of any unlicensed peptide for longevity or anti-ageing purposes is endorsed.
Quick research summary. The longevity research literature (often grouped under the ‘hallmarks of ageing' framework) has explored several peptide and peptide-related compound families in cell-culture and animal-model contexts. The compounds discussed below appear in that research record. None is a licensed UK longevity medicine and most have not been advanced through the MHRA medicines framework.
The ‘hallmarks of ageing' framework
Lopez-Otin and colleagues' hallmarks of ageing framework groups the underlying biology into categories including telomere attrition, mitochondrial dysfunction, cellular senescence, deregulated nutrient sensing, loss of proteostasis, epigenetic alteration, stem-cell exhaustion, altered intercellular communication and others. Peptide research relevant to longevity has touched several of these axes.
Compound families that appear in the research record
The published research record includes work on telomerase-related peptides (Epitalon and similar), mitochondrial-axis peptides (MOTS-c, SS-31 and similar), senolytic and senescence-modulating compound research, NAD-axis and sirtuin-related research, copper-peptide research relevant to oxidative biology (GHK-Cu), and growth-axis peptides relevant to the IGF-1 and growth-hormone systems. These appear in cell-culture and animal-model studies. None is a licensed UK longevity treatment.
UK regulatory position
No peptide sold as a research-use-only reference compound is licensed for longevity or anti-ageing use in the United Kingdom. The MHRA opened investigations in April 2026 into UK clinics making therapeutic claims about unregulated peptide products. The longevity space attracts disproportionate consumer marketing claims and is correspondingly inside the MHRA enforcement scope where claims are made.
For laboratory researchers
Researchers working in ageing biology may use peptide reference compounds for in-vitro and animal-model studies. Quality requirements are batch-specific certificate of analysis, third-party HPLC purity data, mass-spectrometry identity confirmation, and clear research-use-only labelling.
Research use only. The compounds referenced here are research-use-only laboratory reference compounds. Products are not for human or veterinary use.
Informational content for research. This material is educational and intended for laboratory research contexts. It is not medical advice, a prescription, a clinical protocol, or a guarantee of outcome.